FCGR3A and neoplasm: NK92 cells and iPSC-derived NK cells expressing a recombinant receptor containing the extracellular portion of CD64 with the transmembrane and intracellular region of CD16A (referred to as CD64/16A) can kill mAb-opsonized tumor cells in vitro via ADCC better than NK cells expressing the higher affinity CD16A variant [109].